Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Triple Negative Breast Neoplasms 13Breast Neoplasms 11Carcinoma, Transitional Cell 6Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 3Small Cell Lung Carcinoma 2Urothelial Bladder Carcinoma 1Salivary Gland Neoplasms 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Lung Diseases 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1Liver Failure 1HRD Cancer 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Small Cell 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Radiosurgery 28Magnetic Resonance Spectroscopy 15Temozolomide 14pembrolizumab 13Bevacizumab 11Nivolumab 10Ipilimumab 8Memantine 7Specimen Handling 6Radiotherapy 6Mental Status and Dementia Tests 6abemaciclib 5Blood Specimen Collection 5Radiation 4trastuzumab deruxtecan 3entrectinib 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Sodium Chloride 3Saline Solution 3Receptors, Interleukin-8B 3Proton Therapy 3Biopsy 3trametinib 2pertuzumab 2osimertinib 2lenvatinib 2fluciclovine F-18 2contrast agent BR1 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × sacituzumab govitecan × 90 days × Clear all
NCT04647916 2026-05-06

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

SWOG Cancer Research Network

Phase 2 Active not recruiting
44 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡